Interações de Tobramicina

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (bula de Tobramicina, Interações medicamentosas)

Drug Interactions Drugs with Ototoxic Potential (see WARNINGS ) Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. (bula de Bumetanida, Interações medicamentosas)

Aminoglycosides : Avoid concomitant use with aminoglycosides. (bula de Carboplatina, Interações medicamentosas)

In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. (bula de Dicloxacilina, Interações medicamentosas)

Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the potential benefits outweigh the risks to the patient. (bula de Foscarnete, Interações medicamentosas)

TOBI Podhaler should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. (bula de Tobramicina, Interações medicamentosas)

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (bula de Gentamicina, Advertência em caixa preta)

Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (bula de Neomicina, Advertência em caixa preta)

Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (bula de Pentamidina, Interações medicamentosas)

THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED. (bula de Polimixina B, Advertência em caixa preta)

Avoid concomitant use of torsemide and aminoglycoside antibiotics, if possible. (bula de Torasemida, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (bula de Ácido zoledrônico, Interações medicamentosas)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (bula de Adefovir, Advertências e precauções)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (bula de Atracúrio, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Aminoglycosides: Increased potential of nephrotoxicity and ototoxicity. (bula de Cefepima, Interações medicamentosas)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (bula de Cefotaxima, Interações medicamentosas)

If CEFOTAN® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. (bula de Cefotetana, Precauções)

Aminoglycosides: Increased potential of nephrotoxicity. (bula de Cefoxitina, Interações medicamentosas)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. (bula de Cefprozila, Interações medicamentosas)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (bula de Ceftazidima, Interações medicamentosas)

Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. (bula de Ceftriaxona, Interações medicamentosas)

…ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentamicin ketoconazole colchicine ranitidine methotrexate tobramycin diclofenac trimethoprim with sulfamethoxazole naproxen vancomycin sulindac During the concomitant use of a drug that may exhibit additive or synergistic renal impairment… (bula de Ciclosporina, Interações medicamentosas)

The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ). (bula de Cidofovir, Advertências)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (bula de Efavirenz + lamivudina + tenofovir, Interações medicamentosas)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (bula de Elvitegravir + cobicistate + entricitabina + tenofovir, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.5) ] . (bula de Entricitabina + rilpivirina + tenofovir, Interações medicamentosas)

Some examples of drugs that are eliminated by active tubular secretion include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] . (bula de Entricitabina + tenofovir, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (bula de Micofenolato, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. (bula de Piperacilina + tazobactam, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (bula de Rocurônio, Interações medicamentosas)

Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function. (bula de Sirolimo, Advertências e precauções)

The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (bula de Tacrolimo, Advertências e precauções)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.2) ]. (bula de Tenofovir, Interações medicamentosas)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (bula de Toxina botulínica tipo A, Interações medicamentosas)

Aminoglycosides or other agents that interfere with neuromuscular transmission may potentiate the effect of XEOMIN; co-administer only with caution and close observation ( 7 ) (bula de Toxina incobotulínica A, Interações medicamentosas)

Patients receiving concomitant treatment of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of BOTOX may be potentiated ( 7.1 , 7.4 ) (bula de Toxina onabotulínica A, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment. (bula de Vancomicina, Advertências e precauções)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

UNASYN and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of UNASYN. (bula de Ampicilina + sulbactam, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

Drug Interactions Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction. (bula de Colistimetato, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (bula de Piridostigmina, Interações medicamentosas)

Before therapy with ZEMDRI is instituted, careful inquiry about previous hypersensitivity reactions to other aminoglycosides should be made. (bula de Plazomicina, Advertências e precauções)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (bula de Vecurônio, Precauções)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (bula de Tobramicina, Interações medicamentosas)

…assess the need for additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of… (bula de Cisatracúrio, Interações medicamentosas)